TEVA · Categories · Offerings
TEVA - Public offerings
Teva Pharmaceutical Industries Limited (TEVA) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for TEVA
- Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early SettlementTEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Pool 1 Notes");USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN US88167AAP66 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 2 No
- Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") and that it is increasing the tender caps as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 7.125% Senior Notes due 2025, CUSIP 88167AAN1 / ISIN US88167AAN19 (Registered), CUSIP 88167A AM3 / ISIN US88167AAM36 (144A), CUSIP N8540W AC8 / ISIN USN8540WAC84 (Reg S), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 1 Notes"); 6.000% Senior Notes due 2025, Common Code 219821395 / ISIN XS2198213956 (Registered), Common Code 20
- Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early SettlementTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") and that it is increasing the combined aggregate purchase price (exclusive of accrued and unpaid interest) (the "Total Maximum Amount") from $3,500,000,000 to $4,000,000,000 for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 1.250% Senior Notes due 2023, ISIN XS1211040917, issued by Teva Pharmaceutical Finance Netherlands II B.V. (the "Priority 1 Notes"); 2.800% Senior Notes due 2023, CUSIP 88167A AD3 / ISIN US88167AAD37, issued by Teva Pharmaceutical Finance Neth